Uncategorized

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization

Ben Dudley

CANTON, Mich. and READING, UK (July 17, 2024) – MMS, a data-focused clinical research organization (CRO), announced today that Ben Dudley has been appointed as the company’s new Chief Commercial Officer (CCO). Based in the UK, Ben Dudley brings more than 25 years of life sciences expertise on the CRO and Sponsor side, holding previous operational Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

MMS Appoints James Zee as Director for European Biometrics Leadership

CANTON, Michigan, and LONDON (April 4, 2024) – MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming. Based in the United Kingdom (UK), Zee brings 25 years of experience across several leading pharmaceutical companies, MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale

MMS Holdings Inc

Canton, Mich. (March 5, 2024) –MMS Holdings Inc, a distinguished global Clinical Research Organization (CRO), stands at the forefront of supporting pharmaceutical and biotech companies, along with numerous smaller enterprises, across a comprehensive range of services. With an impressive track record of successfully completing over 50 submissions for drug approval in the past five years, MMS MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale

MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

MMS Supported MAPS Public Benefit Corporation NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

Canton, Mich. (December 13, 2023) – MMS, a data-focused Clinical Research Organization (CRO), announced Lykos Therapeutics, formerly known as MAPS Public Benefit Corporation (MAPS PBC) submitted a New Drug Application (NDA) to the FDA for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise

MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise

CANTON, Mich. (March 21, 2023) – MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors. Both industry leaders in innovative clinical trial delivery solutions, Dr. Breitfeld and Dr. Zeiher’s additions as advisors expand MMS’ therapeutic area expertise to support growth in MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise

MMS Partners with I-ACT to Advance Children’s Clinical Trials

MMS Partners with I-ACT to Advance Children’s Clinical Trials

CANTON, Mich. (February 21, 2023) – MMS, a data-focused contract research organization (CRO) – announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics including vaccines, medicines, and medical devices for children. MMS is a sponsor of I-ACT’s Spin Challenge, a creative way to raise funds to advance MMS Partners with I-ACT to Advance Children’s Clinical Trials

Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth

Award-Winning Data CRO Expands Executive Leadership

CANTON, Mich. (2/7/2023) – MMS Holdings (MMS) – an award-winning, data-focused contract research organization (CRO) – announces the expansion of its leadership team with the appointment of Chris Schoonmaker as Chief Operating Officer. This comes as the company was recognized in the 2023 Top Workplace USA awards, a national list of organizations with strong company cultures and high Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth

MMS Named Michigan Top Workplace For The Second Consecutive Year

MMS Named Michigan Top Workplace For The Second Consecutive Year

CANTON, Mich. (11/21/2022) – MMS Holdings, a data-focused contract research organization (CRO), has been named a 2022 award winner of the Michigan Top Workplaces by the Detroit Free Press Top Workplaces. This is the second year that MMS has been recognized with this honor. This award is based on feedback from a confidential survey sent out MMS Named Michigan Top Workplace For The Second Consecutive Year

MMS Holdings Partners with Lindsay Goldberg for Its Next Stage of Growth

MMS Holdings Partners with Lindsay Goldberg for Its Next Stage of Growth

MMS Holdings Inc. (“MMS” or the “Company”), a leading data-focused contract research organization (“CRO”), today announced that Lindsay Goldberg, a leading family and founder-focused private equity firm, has completed an investment in the Company alongside MMS Founder and CEO, Dr. Uma Sharma, who will maintain a significant ownership interest. The partnership will help MMS expand its award-winning services to pharma and biotech companies and extend MMS’ leadership in data-focused clinical research services